Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy

Regenxbio said it has aligned with the FDA on next steps toward potential accelerated approval for Navsunli (RGX-121, clemidsogene lanparvovec). The update is a constructive regulatory milestone for the gene therapy candidate, though it does not represent approval yet. The news is likely company-specific rather than sector-wide.

Analysis

Regenxbio said it has aligned with the FDA on next steps toward potential accelerated approval for Navsunli (RGX-121, clemidsogene lanparvovec). The update is a constructive regulatory milestone for the gene therapy candidate, though it does not represent approval yet. The news is likely company-specific rather than sector-wide.